Skip to content
HowShorted

Arcadia Biosciences, Inc. short interest in 2019

In 2019, Arcadia Biosciences, Inc.'s disclosed short interest ran from 6.29% of shares outstanding on 15 Jan 2019 to 9.20% on 31 Dec 2019, a change of +2.91 percentage points. The year's high was 27.09% on 15 Aug 2019 and its low 1.59% on 15 Jul 2019, averaging 7.99% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.37 days on 15 Jan 2019. Full history: Arcadia Biosciences, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Arcadia Biosciences, Inc. in 2019

2019 in figures

Start of year
6.29% (15 Jan 2019)
End of year
9.20% (31 Dec 2019)
Change
+2.91 pp
High
27.09% (15 Aug 2019)
Low
1.59% (15 Jul 2019)
Average
7.99%
Highest days to cover
7.37 (15 Jan 2019)
SEC filings marked
8

Every report in 2019

Arcadia Biosciences, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 20196.29%7.37
31 Jan 20195.92%3.87
15 Feb 20197.03%1.19
28 Feb 20196.67%1.00
15 Mar 201911.68%1.00
29 Mar 20199.78%2.23results (8-K)
15 Apr 20195.34%1.3010-K filed
30 Apr 20193.53%2.15
15 May 20193.50%1.8410-Q filed, results (8-K)
31 May 20192.93%3.92
14 Jun 20193.10%1.00
15 Jul 20191.59%1.00
31 Jul 20191.88%1.00
15 Aug 201927.09%1.0010-Q filed, results (8-K)
31 Oct 201911.15%1.62
15 Nov 201913.60%1.1910-Q filed, results (8-K)
29 Nov 201910.98%2.82
13 Dec 201910.55%3.04
31 Dec 20199.20%3.39

See also: Arcadia Biosciences, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.